



NEW ZEALAND DATA SHEET

1. NAME OF THE MEDICINAL PRODUCT

SPAZMOL 20 mg/ml Solution for Injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active Substance

Each 1 ml vial contains 20 mg/ml Hyoscine butylbromide.

Excipients:

For a full list of excipients see 6.1.

3. PHARMACEUTICAL FORM

Solution for Injection Clear colorless and odorless solution in colorless glass ampoules.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Muscle spasm of the gastrointestinal tract.

4.2 Posology and method of administration

Adults and adolescents over 12 years:

1 or 2 ampoules (20–40 mg) may be administered by <u>slow</u> intravenous, intramuscular or subcutaneous injection several times a day. A maximum daily dose of 100 mg should not be exceeded.

Infants and young children:

In severe cases, 0.3-0.6 mg/kg bodyweight, to be administered by <u>slow</u> intravenous, intramuscular or subcutaneous injection several times a day .The maximum daily dose of 1.2 mg/kg should not be exceeded.

SPAZMOL should not be taken on a continuous daily basis or for extended periods without investigating the cause of abdominal pain.


4.3 Contraindications

SPAZMOL is contraindicated in myasthenia gravis, mechanical stenosis in the gastrointestinal tract, paralytical or obstructive ileus, megacolon and in patients who have demonstrated prior hypersensitivity to hyoscine butylbromide or any other component of the product.

In addition, SPAZMOL should not be administered parenterally in the following disorders: untreated narrow angle glaucoma; tachycardia and hypertrophy of the prostate with urinary retention.

By intramuscular injection SPAZMOL is contraindicated in patients being treated with anticoagulant medicines since intramuscular hematoma may occur. In these patients, the subcutaneous or intravenous routes may be used.

In case of rare hereditary conditions that may be incompatible with an excipient of the product (please refer to section 4.4) the use of the product is contraindicated.





4.4 Special warnings and precautions for use

In case severe, unexplained abdominal pain persists or worsens, or occurs together with symptoms like fever, nausea, vomiting, changes in bowel movements, abdominal tenderness, decreased blood pressure, fainting or blood in stool, medical advice should immediately be sought where appropriate diagnostic measures are needed to investigate the etiology of the symptoms.

Hyoscine may cause drowsiness: patients so affected should not drive or operate machinery. Patients should abstain from alcohol. However, as a quaternary ammonium compound with low lipid solubility, SPAZMOL cannot cross the blood/brain barrier easily and only rarely causes the central nervous system side effects associated with atropine and hyoscine.

After parenteral administration of SPAZMOL, patients with visual accommodation disturbances should not drive or operate machinery until vision has normalised.

Because of the potential risk of anticholinergic complications, SPAZMOL should be administered with caution in patients susceptible to narrow angle glaucoma, intestinal or urinary outlet obstruction, and those inclined to tachyarrhythmia.

Elevation of intraocular pressure may be produced by the administration of anticholinergics such as hyoscine butylbromide in patients with undiagnosed and therefore untreated narrow angle glaucoma. Therefore, patients should seek urgent ophthalmological advice if they should develop a painful, red eye with loss of vision after the injection of SPAZMOL.

After parenteral administration of hyoscine butylbromide, cases of anaphylaxis including episodes of shock have been observed. As with all medicines causing such reactions, patients receiving SPAZMOL by injection should be kept under observation.

Caution is needed in patients with cardiac conditions submitted to parenteral treatment with SPAZMOL. Monitoring of these patients is advised.

SPAZMOL injection can cause tachycardia, hypotension and anaphylaxis, therefore use with caution in patients with cardiac conditions such as cardiac failure, coronary heart disease, cardiac arrhythmia or hypertension, and in cardiac surgery. Monitoring of these patients is advised. Emergency equipment and personnel trained in its use must be readily available.

Paediatric use

Refer to Section 4.2 for information on paediatric dosing.

4.5 Interaction with other medicinal products and other forms of interaction


The anticholinergic effect of medicines such as tri- and tetracyclic antidepressants, antihistamines, antipsychotics, quinidine, amantadine, disopyramide and other anticholinergics (e.g. tiotropium, ipratropium, atropine-like compounds) may be intensified by SPAZMOL.

Concomitant treatment with dopamine antagonists such as metoclopramide may result in diminution of the effects of both medicines on the gastrointestinal tract.

The tachycardic effects of beta-adrenergic agents may be enhanced by SPAZMOL.

4.6 Fertility, pregnancy and lactation

General advice Pregnancy category is C





Pregnancy

There is limited data from the use of hyoscine butylbromide in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

Lactation

There is insufficient information on the excretion of hyoscine butylbromide and its metabolites in human milk.

As a precautionary measure, it is preferable to avoid the use of SPAZMOL during pregnancy and lactation.

Fertility

No studies on the effects on human fertility have been conducted (see section 5.3).

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, patients should be advised that they may experience undesirable effects such as accommodation disorder or dizziness during treatment with SPAZMOL injection. Therefore, caution should be recommended when driving a car or operating machinery. If patients experience accommodation disorder or dizziness, they should avoid potentially hazardous tasks such as driving or operating machinery.

4.8 Undesirable effects

Many of the listed undesirable effects can be assigned to the anticholinergic properties of hyoscine butylbromide. Anticholinergic side effects of hyoscine butylbromide are generally mild and self-limited. Adverse events have been ranked under headings of frequency using the following convention:

Very common:	≥1/10
Common:	≥1/100, <1/10
Uncommon:	≥1/1,000, <1/100
Rare:	≥1/10,000, <1/1,000
Very rare:	<1/10,000
Not known:	cannot be estimated from the available data

Immune system disorders

Not known: anaphylactic shock including fatal outcome, anaphylactoidic reactions, dyspnea, skin reactions (e.g. urticaria, rash, erythema, pruritus) and other hypersensitivity.

Eye disorders

Common: accommodation disorders *Not known*: mydriasis, increased intraocular pressure.

Cardiac disorders

Common: tachycardia

Vascular disorders (hyoscine butylbromide injection)

Not known: blood pressure decreased, dizziness, flushing.

Gastrointestinal disorders

Common: dry mouth

Skin and subcutaneous tissue disorders *Not known*: dyshidrosis

Renal and urinary disorders

Not known: impaired micturition, urinary retention

Nervous system disorders





Very rarely in the national post marketing surveillance data base, there have been isolated reports following parenteral administration of coma, hallucinations, dystonia, confusion, agitation and dizziness from which the patient recovered after drug withdrawal and appropriate treatment. In very rare cases, dyspnoea has been reported.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorization of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <u>https://nzphyc.otago.ac.nz/reporting/</u>.

4.9 Overdose

Symptoms:

Serious signs of poisoning following acute overdosage have not been observed in man. In case of overdose, anticholinergic symptoms such as urinary retention, dry mouth, reddening of skin, tachycardia, inhibition of gastrointestinal motility, and transient visual disturbances may occur.

Therapy:

In the case of oral poisoning, gastric lavage with activated charcoal should be followed by magnesium sulphate (15%). Symptoms of hyoscine butylbromide overdosage respond to parasympathomimetics. For patients with glaucoma, urgent ophthalmological advice should be sought and pilocarpine should be given locally. If necessary, parasympathomimetics should be administered, e.g. neostigmine 0.5-2.5 mg IM or IV Cardiovascular complications should be treated according to usual therapeutic principles. In case of respiratory paralysis: intubation, artificial respiration should be considered. Catheterization may be required for urinary retention. In addition, appropriate supportive measures should be used as required.

In case of overdose, immediately contact the Poisons Information Centre for advice, in New Zealand, (0800 POISON or 0800 764 766).

Drug abuse and dependence:

Drug dependency, addiction and recreational abuse have not been reported as a problem with this compound.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Quanternary ammonium derivate ATC code: A03BB01

Mechanism of action:


Hyoscine-*N*-butylbromide exerts a spasmolytic action on the smooth muscle of the gastrointestinal, biliary and urinary tracts. As a quaternary ammonium derivative, hyoscine butylbromide does not enter the central nervous system. Therefore, anticholinergic side effects at the central nervous system do not occur. Peripheral anticholinergic effects result from a ganglion-blocking action within the visceral wall as well as from anti-muscarinic activity.

5.2 Pharmacokinetic properties

General properties

Absorption:

As a quaternary ammonium compound, hyoscine butylbromide is highly polar and hence only partially absorbed following oral (8%) administration. After oral administration of single doses of hyoscine butylbromide in the range of 20 to 400 mg, mean peak plasma concentrations between 0.11 ng/ml and 2.04 ng/ml were found at approximately 2 hours. In the same dose range, the observed mean AUC_{0-tz}-values varied from 0.37 to 10.7 ng h/ml. The median absolute bioavailabilities of different dosage forms, i.e. coated tablets,





suppositories and oral solution, containing 100 mg of hyoscine butylbromide each were found to be less than 1%.

Distribution:

After intravenous administration hyoscine butylbromide is rapidly distributed ($t_{1/2\alpha} = 4 \text{ min}$, t $t_{1/2\beta} = 29 \text{ min}$) into the tissues. The volume of distribution (Vss) is 128 L (corresponding to approx. 1.7 L/kg).

Because of its high affinity for muscarinic receptors and nicotinic receptors, hyoscine butylbromide is mainly distributed on muscle cells of the abdominal and pelvic area as well as in the intramural ganglia of the abdominal organs. Plasma protein binding (albumin) of hyoscine butylbromide is approximately 4.4%. Animal studies demonstrate that hyoscine butylbromide does not pass the blood-brain barrier, but no clinical data to this effect is available. Hyoscine butylbromide (1 mM) has been observed to interact with the choline transport (1.4 nM) in epithelial cells of human placenta *in vitro*.

Metabolism and elimination:

Following oral administration of single doses in the range of 100 to 400 mg, the terminal elimination half-lives ranged from 6.2 to 10.6 hours. The main metabolic pathway is the hydrolytic cleavage of the ester bond. Orally administered hyoscine butylbromide is excreted in the feces and in the urine. Studies in man show that 2 to 5% of radioactive doses are eliminated renally after oral and 0.7 to 1.6% after rectal administration. Approximately 90% of recovered radioactivity can be found in the faeces after oral administration. The urinary excretion of hyoscine butylbromide is less than 0.1% of the dose. The mean apparent oral clearances after oral doses of 100 to 400 mg range from 881 to 1420 L/min, whereas the corresponding volumes of distribution for the same range vary from 6.13 to 11.3×10^5 L, probably due to very low systemic availability. The metabolites excreted via the renal route bind poorly to the muscarinic receptors and are therefore not considered to contribute to the effect of the hyoscine butylbromide.

The half-life of the terminal elimination phase $(t_{1/2\gamma})$ is approximately 5 hours. The total clearance is 1.2 L/min. Clinical studies with radiolabeled hyoscine butylbromide show that after intravenous injection 42 to 61% of the radioactive dose is excreted renally and 28.3 to 37% fecally. The portion of unchanged active ingredient excreted in the urine is approximately 50%. The metabolites excreted via the renal route bind poorly to the muscarinic receptors and are therefore not considered to contribute to the effect of the hyoscine butylbromide.

5.3 Preclinical safety data


Acutely, hyoscine butylbromide has a low index of toxicity: oral LD₅₀ values were 1000-3000 mg/kg in mice, 1040-3300 mg/kg in rats, and 600 mg/kg in dogs. Toxic signs were ataxia and decreased muscle tone, additionally, in mice tremor and convulsions, in dogs mydriasis, dry mucous membranes and tachycardia. Deaths from respiratory arrest occurred within 24 h. The intravenous LD₅₀ values of hyoscine butylbromide were 10-23 mg/kg in mice and 18 mg/kg in rats.

In repeated oral dose toxicity studies over 4 weeks, rats tolerated 500 mg/kg = "no observed adverse effect level (NOAEL)". At 2000 mg/kg, by the action on parasympathetic ganglia of visceral area, hyoscine butylbromide paralyzed the gastrointestinal function resulting in obstipation. Eleven out of 50 rats died. Hematology and clinical chemistry results did not show dose-related variations.

Over 26 weeks, rats tolerated 200 mg/kg, while at 250 and 1000 mg/kg, the gastro-intestinal function was depressed and deaths occurred. The NOAEL of the 39-week oral (capsule) dog study was 30 mg/kg. The majority of clinical findings were attributable to acute effects of hyoscine butylbromide at high dosages (200 mg/kg). No adverse histopathological findings were observed.

A repeated intravenous dose of 1 mg/kg was well tolerated by rats in a 4-week study. At 3 mg/kg, convulsions occurred immediately after injection. Rats dosed with 9 mg/kg died from respiratory paralysis.

Dogs treated intravenously over 5 weeks at 2×1 , 2×3 and 2×9 mg/kg, showed a dose-dependent mydriasis in all treated animals, in addition at 2×9 mg/kg, ataxia, salivation and decreased body weight and food intake were observed. The solutions were locally well tolerated.





After repeated IM injection, the dose of 10 mg/kg was systemically well tolerated, but lesions of muscles at the site of injection were distinctly increased if compared to control rats. At 60 and 120 mg/kg, mortality was high and local damages were dose-dependently increased.

Hyoscine butylbromide was neither embryotoxic nor teratogenic at oral doses of up to 200 mg/kg in the diet (rat) and 200 mg/kg by gavage or 50 mg/kg SC (rabbit). Fertility was not impaired at doses of up to 200 mg/kg PO.

Like other cationic medicines, hyoscine butylbromide interacts with the choline transport system of human placental epithelial cells *in vitro*. Transfer of hyoscine butylbromide to the fetal compartment has not been proved.

Hyoscine butylbromide-suppositories were locally well tolerated.

In special studies concerning local tolerability, a repeated IM injection of 15 mg/kg hyoscine butylbromide over 28 days was studied in dogs and monkeys. Small focal necroses at the site of injection were seen only in dogs. Hyoscine butylbromide was well tolerated in arteries and veins of the rabbit's ear. *In vitro*, 2 % hyoscine butylbromide injectable solution showed no hemolytic action when mixed with 0.1 ml human blood.

Hyoscine butylbromide revealed no mutagenic or clastogenic potential in the Ames test, in the *in vitro* gene mutation assay in mammalian V79 cells (HPRT test) and in an *in vitro* chromosome aberration test in human peripheral lymphocytes. In vivo, hyoscine butylbromide was negative in the rat bone marrow micronucleus assay.

There are no *in vivo* carcinogenicity studies. Nevertheless, hyoscine butylbromide did not show a tumorigenic potential in two oral 26-week-studies in rats given up to 1000 mg/kg.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

Sodium chloride and hydrochloric acid (for pH adjustment) Water for injections.

6.2 Incompatibilities

None known

6.3 Shelf life

36 months

6.4 Special precautions for storage

Store at room temperature below 25°C.

6.5 Nature and contents of container


In clear glass ampoules of 1 ml in packages of 3, 5 or 6 ampoules.

6.6 Special precautions for disposal and other handling

Any unused material should be disposed according to local disposal regulations.

7. MEDICINE SCHEDULE

Prescription Medicine





8. SPONSOR

DEVATIS LIMITED Findex, 173 Spey Street, Invercargill 9810, New Zealand Toll Free Number: 0800 887750 www.devatis.nz

9. DATE OF FIRST APPROVAL

16.01.2020

10. DATE OF REVISION OF THE TEXT

13.09.2024